| Name | Title | Contact Details |
|---|---|---|
Jason Kawata |
Vice President of Technology, Food Division | Profile |
Sonoma Biotherapeutics is inventing the future of living therapies for autoimmune disease — safe, effective treatments as unique as each individual patient. Regulatory T cell therapies that harness a patient`s own immune cells, powerful next generation gene editing techniques and advanced manufacturing and quality assurance processes. Sonoma`s mission is to create a best-in-class regulatory T cell therapy that delivers long-lasting, highly efficacious treatments leading to cures across a spectrum of autoimmune and degenerative diseases.
Ribon Therapeutics is a biotech company focused on developing first-in-class therapeutics targeting mono(ADP-ribosyl)ating PARPs for cancer.
Inscripta is a gene-editing technology company dedicated to creating the tools needed to revolutionize how we feed, fuel, and heal humanity.
HotSpot Therapeutics is discovering new allosteric therapies with the ability to treat disease in new ways.
We are a biotechnology company integrating AI, computation and biological automation to accelerate the design of small molecule and protein therapeutics. Our mission is to decrease the timeline and cost of drug development, while improving the success rate of bring innovative medicines to patients in need.